Dr. Peter Engel, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1971)
- Years since graduation
- 55
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 222
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1971Medical school: New York University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OH license 35035963
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christ Hospital Cincinnati, OH
Medical groups
- The Christ Hospital Cardiovascular Associates LLC (152 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 222
- Services billed
- 982
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 359 | 200 |
| Established patient office or other outpatient visit, 30-39 minutes | 279 | 157 |
| Established patient office or other outpatient visit, 40-54 minutes | 164 | 76 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 83 | 82 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
| Heart muscle strain imaging | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Opsumit (macitentan) | 305 |
| Furosemide Other prescribers in Cincinnati, OH | 202 |
| Tadalafil | 183 |
| Uptravi (selexipag) | 152 |
| Potassium Chloride Other prescribers in Cincinnati, OH | 135 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 132 |
| Torsemide Other prescribers in Cincinnati, OH | 123 |
| Spironolactone Other prescribers in Cincinnati, OH | 111 |
| Carvedilol Other prescribers in Cincinnati, OH | 111 |
| Amlodipine Besylate Other prescribers in Cincinnati, OH | 107 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 18 payments worth $831 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $324 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $234 |
| United Therapeutics Corporation | $142 |
| Merck Sharp & Dohme LLC | $112 |
| AstraZeneca Pharmaceuticals LP | $19.23 |
| Food and Beverage | $579 |
|---|---|
| Consulting Fee | $200 |
| Education | $51.40 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $248,071 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Merck Sharp & Dohme LLC - An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Ma…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.